Drug Profile
Research programme: neurodegenerative disorders therapeutics - Aurogen
Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Aurogen
- Class Growth factors; Intercellular signalling peptides and proteins
- Mechanism of Action Insulin-like growth factor I stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Alzheimer's disease; Diabetic neuropathies
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for research development in Alzheimer's-disease in USA (Parenteral)
- 16 Jul 2016 No recent reports of development identified for research development in Diabetic-neuropathies in USA (Parenteral)
- 19 Nov 2008 Early research in Alzheimer's disease in USA (Parenteral)